A Study of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
A Phase 1 Trial of JNJ-99220732 in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to find out how safe and well-tolerated JNJ-99220732 is and to find out the most suitable dose ([putative] recommended phase 2 dose [pRP2D] regimen[s]) of JNJ-99220732 (Part 1-Dose Escalation). Also, to find out how safe and well-tolerated JNJ-99220732 is at the pRP2D regimen(s) as determined in Part 1 (Part 2- Dose Expansion).
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Study Contact
- 電話番号:844-434-4210
- メール:Participate-In-This-Study1@its.jnj.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion criteria:
- Histological or cytological diagnosis of locally advanced, or metastatic solid tumor, received greater than or equal to (>=) 1 prior line of therapy for recurrent or metastatic disease; progressed or relapsed after or be intolerant to standard therapy approved for the specific tumor type. Participants who actively decline available standard of care therapies are eligible upon documentation of their refusal.
i. Participants with NSCLC must not have known actionable driver alteration for which a targeted therapy is available.
ii. Demonstrated radiographic progression on most recent tumor assessment imaging
- Participants entering the study must have >=1 measurable lesion as defined by response evaluation criteria in solid tumors (RECIST) version 1.1 that has not been previously irradiated
- Body weight >=35 kilogram (kg) and body mass index (BMI) >=18 kilogram per square meter (kg/m^2)
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Must provide informed consent as described in protocol which includes compliance with the requirements and restrictions listed in the protocol and in the informed consent form (ICF)
Exclusion criteria:
- Active central nervous system (CNS) involvement with the exception of brain metastases that are clinically stable and asymptomatic for greater than (>)2 weeks off treatment and who are off or receiving low-dose corticosteroid treatment for at least 2 weeks prior to first dose of study treatment
- Any other malignancy diagnosis other than the disease under study within 2 years prior to the first dose of study treatment, except for squamous and basal cell carcinoma of the skin, non-muscle invasive bladder cancer, or any malignancy considered cured or has minimal risk of recurrence within 1 year of first dose of study treatment
- Had major surgery within 14 days prior to first dose of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to participate in the trial
- External beam radiation therapy to soft tissue lesions within 14 days prior to start of study treatment
- History of solid organ or allogeneic hematopoietic stem cell transplant (HSCT)
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:JNJ-99220732 (Part 1 and Part 2)
Participants will receive escalating doses of JNJ-99220732 to identify the (putative) recommended phase 2 dose (pRP2D) regimen(s) in Part 1 (dose escalation) of the study. In Part 2 (dose expansion), participants will receive JNJ-99220732 at the pRP2D regimen(s) determined in Part 1 until lost to follow-up, withdrawal of consent, start of subsequent anticancer therapy, completion of the post treatment follow-up or the sponsor decides to stop the trial, whichever occurs first. |
JNJ-99220732 will be administered intravenously. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Number of Participants with Adverse Events (AE) by Severity
時間枠:Up to 3 years 2 months
|
An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the intervention. An assessment of severity grade will be made by the investigator according to the National cancer institute common terminology criteria for Adverse Events (NCI-CTCAE version 6.0) using the standard grades as follows: Grade 1- Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated; Grade 2- Moderate; minimal, local or noninvasive intervention indicated; limiting age appropriate instrumental activities of daily living (ADL); Grade 3- Severe or medically significant but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL; Grade 4- Life-threatening consequences; urgent intervention indicated; Grade 5- Death related to adverse event. |
Up to 3 years 2 months
|
|
Part 1: Number of Participants with Dose Limiting Toxicities (DLTs)
時間枠:Up to 21 days
|
A DLT is defined as any adverse event that is not clearly due to the underlying disease or extraneous causes that occurs during the DLT period. It includes any toxicity resulting in permanent treatment discontinuation or a delay in dosing of greater than (>)14 days, any Grade 5 toxicity and any death not clearly due to underlying disease or non-study treatment-related cause, high-grade hematological and non-hematological toxicities. |
Up to 21 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Serum Concentration Time Profile of JNJ-99220732
時間枠:Up to 3 years 2 months
|
Serum concentrations of JNJ-99220732 over time will be reported. |
Up to 3 years 2 months
|
|
Maximum Observed Concentration (Cmax) of JNJ-99220732
時間枠:Up to 3 years 2 months
|
Cmax of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Trough Concentration (Ctrough) of JNJ-99220732
時間枠:Up to 3 years 2 months
|
Ctrough of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Time to Maximum Concentration (Tmax) of JNJ-99220732
時間枠:Up to 3 years 2 months
|
Tmax of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Area Under the Concentration-Time Curve from Time Zero to Last Measured Time Point (AUC 0-tau) of JNJ-99220732
時間枠:Up to 3 years 2 months
|
AUC0-tau of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Accumulation Ratio of JNJ-99220732
時間枠:Up to 3 years 2 months
|
Accumulation ratio of JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Number of Participants with Anti-Drug Antibodies Against JNJ-99220732
時間枠:Up to 3 years 2 months
|
Number of participants with anti-drug antibodies against JNJ-99220732 will be reported. |
Up to 3 years 2 months
|
|
Objective Response Rate
時間枠:Up to 3 years 2 months
|
Objective Response Rate (ORR) is defined as percentage of participants with best objective response of complete response (CR) or partial response (PR) based on response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) criteria. |
Up to 3 years 2 months
|
|
Disease Control Rate (DCR)
時間枠:Up to 3 years 2 months
|
DCR is defined as the percentage of participants who achieve a confirmed best overall response of CR, PR, or stable disease (SD) based on RECIST version 1.1. |
Up to 3 years 2 months
|
|
Radiographic Progression-Free Survival (rPFS)
時間枠:Up to 3 years 2 months
|
Radiographic PFS was defined as the time (in months) interval from first dose to the first date of radiographic progression or death. Radiographic progression included progression by bone scan, defined as at least 2 new lesions on bone scan and progression of soft tissue lesions by computed tomography (CT) or magnetic resonance imaging (MRI) (according to RECIST v.1.1 criteria). |
Up to 3 years 2 months
|
|
Duration of Response (DOR)
時間枠:Up to 3 years 2 months
|
DOR is defined as time from date of first documented response (CR/PR) until date of first documented progressive disease (PD) or death, whichever occurs first (according to RECIST v.1.1 criteria). |
Up to 3 years 2 months
|
協力者と研究者
捜査官
- スタディディレクター:Janssen Research & Development LLC Clinical Trial、Janssen Research & Development, LLC
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 99220732STM1001
- 2026-527759-24-00 (レジストリ識別子:EUCT number)
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。